Inventiva (NASDAQ:IVA) Research Coverage Started at Truist Financial

Truist Financial started coverage on shares of Inventiva (NASDAQ:IVA) in a research report sent to investors on Thursday, MarketBeat reports. The firm issued a buy rating and a $13.00 price target on the stock.

IVA has been the subject of several other reports. UBS Group began coverage on Inventiva in a report on Wednesday, January 7th. They set a “buy” rating and a $12.00 target price for the company. Barclays started coverage on Inventiva in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price target on the stock. HC Wainwright set a $24.00 price objective on Inventiva and gave the company a “buy” rating in a research report on Wednesday, January 28th. Leerink Partners initiated coverage on shares of Inventiva in a report on Monday, January 12th. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $16.56.

Inventiva Price Performance

Inventiva stock opened at $5.78 on Thursday. The firm has a fifty day simple moving average of $6.30 and a two-hundred day simple moving average of $5.36. Inventiva has a twelve month low of $2.70 and a twelve month high of $7.98.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IVA. Wealth Enhancement Advisory Services LLC grew its position in shares of Inventiva by 55.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after buying an additional 9,212 shares during the last quarter. Creative Planning bought a new position in shares of Inventiva during the second quarter valued at approximately $32,000. Commonwealth Equity Services LLC lifted its stake in Inventiva by 19.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock worth $361,000 after acquiring an additional 12,704 shares during the period. Virtu Financial LLC bought a new stake in Inventiva in the fourth quarter valued at $60,000. Finally, XTX Topco Ltd bought a new stake in Inventiva in the fourth quarter valued at $84,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.